Inmune Bio Earnings Call Balances Progress and Risk

Inmune Bio ((INMB)) has held its Q4 earnings call. Read on for the main highlights of the call.

Inmune Bio’s latest earnings call painted a mixed but intriguing picture for investors. Management highlighted solid clinical and regulatory progress across multiple programs, yet this momentum was counterbalanced by a key trial miss, a sizeable impairment charge, and a cash position that limits runway to early 2027, keeping sentiment cautiously balanced rather than outright bullish.

CORDStrom Delivers Strong RDEB Efficacy and Safety Data

Randomized, placebo‑controlled results for CORDStrom in recessive dystrophic epidermolysis bullosa showed clinically meaningful wound healing, reduced itch, and quality‑of‑life gains alongside a favorable safety profile. Inmune plans to file a U.K. marketing application by mid‑summer 2026, with EMA and U.S. submissions by year‑end and potential patient supply beginning in 2027.

CORDStrom Manufacturing and Mechanism Strengthen Regulatory Case

The company reported reproducible manufacturing from pooled donor MSC banks, with four distinct master seedstocks performing consistently batch‑to‑batch. Established potency assays and a defined mechanism involving M1‑to‑M2 macrophage modulation and IL‑10 induction are critical CMC pillars that support future filings and potential commercialization.

XPro in Alzheimer’s Shows Signal Despite Trial Shortfall

Although the MINDFuL study missed its clinical primary endpoint, management said key measures consistently favored XPro across clinical, behavioral, patient‑reported, blood and imaging biomarkers. The FDA has now provided End‑of‑Phase‑II feedback, aligning with an adaptive Phase III trial that could convert a Phase IIb readout into a seamless registrational stage.

INKmune Phase II in mCRPC Hits Key Milestones

INKmune continued to be a quiet positive as the Phase II metastatic castration‑resistant prostate cancer trial was completed ahead of schedule and under budget. The study met its primary endpoint and two of three secondary endpoints, giving Inmune additional optionality for further development and prospective business development discussions.

R&D Spending Falls Sharply, Boosting Capital Efficiency

Research and development expense declined to about $20.7 million in 2025, down from $33.2 million a year earlier, a roughly 37.7 percent reduction. Management attributed the drop primarily to lower Alzheimer’s trial costs, improving near‑term capital efficiency while still advancing core assets.

Fresh Equity Raises Extend, But Do Not Solve, Runway

Inmune secured roughly $27.5 million in net proceeds during 2025 through a $17.4 million registered direct offering and about $10.1 million from at‑the‑market share sales. These financings help bridge the company toward pivotal clinical and regulatory milestones but underscore its ongoing reliance on external capital.

MINDFuL Miss and Intangible Impairment Weigh on Results

The failure of the MINDFuL Phase II Alzheimer’s trial to meet its top‑line primary endpoint triggered a full write‑down of a $16.5 million intangible asset in 2025. The impairment not only pressured reported earnings but also highlighted the clinical risk still embedded in the XPro program despite encouraging biomarker trends.

Net Loss Widens as Development Stage Costs Persist

Net loss attributable to common stockholders rose to approximately $45.9 million in 2025, compared with $42.1 million in 2024, an increase of about nine percent. The higher loss reflects ongoing development‑stage spending combined with the Alzheimer’s‑related intangible impairment, even as R&D outlays trended lower.

Cash Tight and Runway Finite, Forcing Funding Decisions

Cash and cash equivalents stood at around $24.8 million at the end of 2025, and management believes this funds operations only through the first quarter of 2027. With capital‑intensive plans for an Alzheimer’s Phase III and CORDStrom commercialization, investors should expect additional financing moves or partnering activity.

Share Dilution Highlights Funding Trade‑Offs for Investors

To secure needed capital, Inmune issued roughly 4.3 million new shares in 2025, lifting common shares outstanding to about 26.6 million by late March 2026. While these equity raises extended runway, they diluted existing shareholders, spotlighting the balance between funding growth and preserving per‑share value.

Added U.S. Regulatory Steps Raise CMC Complexity

For CORDStrom’s U.S. pathway, the FDA is requiring cord donors to be screened in U.S.‑accredited laboratories, forcing Inmune to generate new master seedstocks from U.S.‑tested donors. This adds operational and CMC complexity to the planned BLA and introduces another execution step that could influence timing.

G&A Creep Adds to Overall Burn Rate

General and administrative expenses increased to about $10.3 million in 2025 from $9.5 million in 2024, an 8.4 percent rise. The uptick in overhead, though modest, adds to the overall cash burn at a time when the company is trying to carefully manage resources ahead of expensive late‑stage trials.

Guidance Points to Busy 2026–2027 Catalyst Calendar

Management guided to a mid‑2026 U.K. filing for CORDStrom, followed by EMA and FDA submissions later that year and potential 2027 feedback plus initial patient supply, with orphan and rare pediatric status offering upside via priority review. For XPro, the agreed adaptive Phase III will use a nine‑month Phase IIb decision point and an 18‑month CDR‑Sum of Boxes primary endpoint, while INKmune’s completed Phase II and current cash runway into Q1 2027 frame both opportunity and funding urgency.

Inmune Bio’s call left investors weighing compelling scientific and regulatory traction against real financial and execution risks. With pivotal CORDStrom filings on deck, an FDA‑endorsed Phase III design for XPro, and encouraging INKmune data, the upside is tangible, but constrained cash, dilution and recent Alzheimer’s setbacks argue for a balanced, risk‑aware stance on the stock.